Meeting
2020 ASCO Virtual Scientific Program
Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
Authors
Liv Johannessen
Syros Pharmaceuticals, Cambridge, MA
Liv Johannessen , Nan Ke , Priyanka Sawant , Wojciech Dworakowski , Anthony D'Ippolito , Shanhu Hu , Nisha Rajagopal , Matthew Eaton , Graeme Hodgson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3585)
DOI
10.1200/JCO.2020.38.15_suppl.3585
Abstract #
3585
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.
First Author: Saikat Chowdhury
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.
First Author: Khalid Jazieh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer.
First Author: Svea Cheng